Skip to main content

Table 4 Logistic regression models for the early prediction of persistent AKI

From: Urine cell cycle arrest biomarkers distinguish poorly between transient and persistent AKI in early septic shock: a prospective, multicenter study

Variable included Clinical model Model 2
Odds ratio [95% CI] p value Odds ratio [95% CI] p value
Total cohort (n = 184)
 Baseline SOFA without renal component 1.16 [1.01–1.33] 0.02 1.16 [1.01–1.32] 0.03
 Baseline urine output (ml/kg/h) 0.28 [0.16–0.49] < 0.001 0.32 [0.19–0.56] < 0.001
 Baseline SCr concentration* (μmol/l) 1.30 [1.08–1.56] 0.005 1.30 [1.08–1.56] 0.006
 Baseline [TIMP-2]*[IGFBP7]    1.04 [0.98–1.11] 0.2
 Norepinephrine dose at inclusion (μg/kg/min) 2.75 [1.22–6.20] 0.01 2.67 [1.19–6.03] 0.02
AUROC 0.81 [0.74–0.86] 0.81 [0.74–0.86]
Brier score# 0.18 0.17
Moderate to severe AKI (n = 90)
 Baseline SOFA without renal component 1.37 [1.09–1.73] 0.008 1.39 [1.09–1.76] 0.007
 Baseline urine output (ml/kg/h) 0.18 [0.07–0.46] < 0.001 0.19 [0.07–0.49] < 0.001
 Baseline SCr concentration* (μmol/l) 1.22 [0.95–1.58] 0.1 1.23 [0.95–1.59] 0.1
 Baseline [TIMP-2]*[IGFBP7]    1.01 [0.95–1.08] 0.7
 Norepinephrine dose at inclusion (μg/kg/min) 4.55 [1.12–18.45] 0.03 4.32 [1.07–17.46] 0.04
AUROC 0.86 [0.77–0.92] 0.86 [0.77–0.92]
Brier score# 0.19 0.19
  1. Data are presented as odds ratios [95% confidence intervals]. The population is divided into two groups according to AKI severity at inclusion
  2. TIMP-2 tissue inhibitor of metalloproteinases-2, IGFBP-7 insulin-like growth factor-binding protein 7, SOFA Sequential Organ Failure Assessment, SCr serum creatinine
  3. *For each 50 μmol/l increase
  4. #The maximum value expected is 0.25, given the prevalence of persistent AKI in the cohort (46%)